Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED

CHAARTED was an ECOG-led phase III trial looking at early chemotherapy with the use of docetaxel in addition to androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer. The positive results of the trial showing marked improvement in overall survival in those who rece...

Descripción completa

Detalles Bibliográficos
Autor principal: Aragon-Ching, Jeanny B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Invited Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854101/
https://www.ncbi.nlm.nih.gov/pubmed/26510505
http://dx.doi.org/10.4103/1008-682X.164920
Descripción
Sumario:CHAARTED was an ECOG-led phase III trial looking at early chemotherapy with the use of docetaxel in addition to androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer. The positive results of the trial showing marked improvement in overall survival in those who received chemotherapy with ADT have revolutionized the treatment of metastatic castration-sensitive prostate cancer. In addition to overall survival, secondary endpoints such as time to castration resistance, PSA response were also significant for the patients who received early chemotherapy.

Ejemplares similares